18F-BMS-986192 PET to Predict Durable Response to Nivolumab in NSCLC: A Novel Approach Beyond PD-L1 Immunohistochemistry.
Programmed death ligand 1 (PD-L1) immunohistochemistry, the current standard biomarker for predicting response to programmed death protein 1/PD-L1 checkpoint inhibitors in non-small cell lung cancer, has moderate predictive value among others because of tumor heterogeneity and limited biopsy representation, whereas PD-...